Nine to forty-two (42 patients only if every cohort required expansion) total patients are planned for this phase 0/1 study to explore the ability of letrozole to penetrate the blood brain barrier and gliomas.
The purpose of this study is to determine the ability of letrozole to penetrate the blood brain barrier and concentrate in gliomas.